A Phase 3 interventional study of BEMA™ and Placebo in Pain and Cancer, sponsored by BioDelivery Sciences International. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-18.
Sponsored by BioDelivery Sciences International · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,882 studies in Pain with a site in United States — 313 open to participants now, 392 under way, 24 of them phase 3. Pain · United States.
Among the 2,882 studies in Pain with a site in United States, this one is the 627th largest by enrollment of the 2,560 interventional ones that give a count, is one of 107 that started in 2006, is one of 343 in phase 3, and was the 199th registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →313 of the 2,882 studies in Pain with a site in United States are open now. Recruiting first, the newest first:
Yale University · Sites in United States
Ages 30–75
Vanderbilt University Medical Center · Sites in United States
Ages 18+
Columbia University · Sites in United States
Ages 6–17
Hospital for Special Surgery, New York · Sites in United States
Ages 18–80 · Healthy volunteers
Ambros Therapeutics, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,882 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 249 · Phase 2 416 · Phase 3 375 · Phase 4 372
First in 1957; this study’s year is marked. 107 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 152 is above the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 66 across the 2,560 interventional studies, 99 across the 299 observational. Of the 2,225 that completed or were terminated, 1,051 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
670 of 2,882 have an industry lead sponsor. The 10 most frequent:
BioDelivery Sciences International is the lead sponsor of 21 studies on the registry; 1 is open to participants now.
BioDelivery Sciences International has 9 studies filed under Pain — fewer than ten, so there is no comparison to draw.
172 of the studies in Pain with a site in United States that are under way reach primary completion within a year, 11 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05000281Phase 3Major Extremity Trauma Research ConsortiumEffect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Fractures | 2026-11-30 |
| NCT07226258Phase 3Saol Therapeutics IncPhase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain | 2026-11-30 |
| NCT05964868Phase 3Jessyka LighthallEfficacy of Liposomal Bupivacaine Post Septorhinoplasty | 2026-12 |
| NCT07832552Phase 3Harrow IncA Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery | 2026-12 |
| NCT03823534Phase 3St. Louis UniversityPost-Op Pain Control for Prophylactic Intramedullary Nailing. | 2026-12-31 |
Add all 172 to your calendar (.ics) → With an account.
Among the 2,882 studies in Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of BEMA Fentanyl (Onsolis) at any dose in the management of breakthrough pain in cancer subjects on background opioid therapy. The standard of care for these breakthrough pain episodes is a rapid onset, short acting analgesic with minimal associated sleepiness. Oral morphine, oxycodone and hydromorphone are routinely used, but because of slow and variable oral absorption, the pain control is not the best with these products. Oral transmucosal fentanyl citrate (OTFC) has been used successfully in treating breakthrough pain episodes associated with cancer. OTFC is a lozenge of fentanyl on a stick and is administered by continuously swabbing the interior of the subject's mouth until the product is dissolved (approximately 15 to 30 minutes). The buccal route of administration avoids the delay and variability associated with oral absorption.
This is a randomized, double-blind, placebo controlled, multiple cross-over study. Eligible subjects will be treated with open label BEMA fentanyl over a period of up to two weeks. Doses will be titrated upward, starting at 200 μg, until a dose is identified that produces satisfactory pain relief for at least 2 episodes. Those subjects who identify a dose of BEMA fentanyl that produces satisfactory relief of breakthrough pain episodes will enter the double-blind, placebo controlled period of the trial. They will receive 3 placebo doses and 6 BEMA fentanyl doses in a random sequence per randomization schedule.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo
Drug: BEMA™ · Drug: Placebo
BioErodible MucoAdhesive (BEMA) Fentanyl
Drug: BEMA™
BioDelivery Sciences International, Inc. (BDSI) has developed BioErodible MucoAdhesive (BEMA) Fentanyl, an alternative product to OTFC that does not require the subject to continuously paint the inside of the mouth with the dosage form. The BDSI product is a small soluble film that is placed against the mucosal membrane inside the mouth. The mucoadhesive polymers in the film readily adhere to the mucosal membrane (within 5 seconds) when moistened. The components of the film are water soluble, so the entire dosage form dissolves within 30 minutes of application.
Also known as: Onsolis (fentanyl buccal soluble film)
Summary of Pain Intensity Differences (SPID)
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome.
Time frame: 0-30 minutes
SPID
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome.SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest.
Time frame: 0-5 minutes
SPID
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome.SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest.
Time frame: 0-10 minutes
SPID
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome.SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest.
Time frame: 0-15 minutes
SPID
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome.SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest.
Time frame: 0-45 minutes
SPID
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome.SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest.
Time frame: 0-60 minutes
PID
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.
Time frame: 5 minutes after dosing
PID
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.
Time frame: 10 minutes after dosing
PID
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.
Time frame: 15 minutes after dosing
PID
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.
Time frame: 30 minutes after dosing
PID
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.
Time frame: 45 minutes after dosing
PID
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.
Time frame: 60 minutes after dosing
Pain Relief
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.
Time frame: 5 minutes after dosing
Pain Relief
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.
Time frame: 10 minutes after dosing
Pain Relief
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.
Time frame: 15 minutes after dosing
Pain Relief
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.
Time frame: 30 minutes after dosing
Pain Relief
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.
Time frame: 45 minutes after dosing
Pain Relief
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.
Time frame: 60 minutes after dosing
Total Pain Relief
Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest.Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)
Time frame: 5 minutes
Total Pain Relief
Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest. Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)
Time frame: 10 minutes
Total Pain Relief
Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest. Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)
Time frame: 15 minutes
Total Pain Relief
Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest. Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)
Time frame: 30 minutes
Total Pain Relief
Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest. Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)
Time frame: 45 minutes
Total Pain Relief
Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest. Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)
Time frame: 60 minutes
Subject Overall Satisfaction With Study Drug
Subjects evaluated their overall satisfaction with study drug at the time rescue medication was consumed or at the 60-minute time point using a 5-point categorical scale (0 = poor, 1 = fair, 2 = good, 3 = very good, and 4 = excellent).
Time frame: 60 minutes or at time of rescue medication use
Percentage of Pain Free Episodes
A pain free episode is one with 0 pain intensity at the specified time point. Percentage of episodes that are pain-free per subject is analyzed.
Time frame: 5 minutes
Percentage of Pain Free Episodes
A pain free episode is one with 0 pain intensity at the specified time point. Percentage of episodes that are pain-free per subject is analyzed.
Time frame: 10 minutes
Percentage of Pain Free Episodes
A pain free episode is one with 0 pain intensity at the specified time point. Percentage of episodes that are pain-free per subject is analyzed.
Time frame: 15 minutes
Percentage of Pain Free Episodes
A pain free episode is one with 0 pain intensity at the specified time point. Percentage of episodes that are pain-free per subject is analyzed.
Time frame: 30 minutes
Percentage of Pain Free Episodes
A pain free episode is one with 0 pain intensity at the specified time point. Percentage of episodes that are pain-free per subject is analyzed.
Time frame: 45 minutes
Percentage of Pain Free Episodes
A pain free episode is one with 0 pain intensity at the specified time point. Percentage of episodes that are pain-free per subject is analyzed.
Time frame: 60 minutes
Episodes With at Least 50% Decreases in Pain
Number of episodes where the total pain score has at least a 50% reduction from baseline.
Time frame: 15 minutes
Episodes With at Least 50% Decreases in Pain
Number of episodes where the total pain score has at least a 50% reduction from baseline.
Time frame: 30 minutes
Episodes With at Least 50% Decreases in Pain
Number of episodes where the total pain score has at least a 50% reduction from baseline.
Time frame: 45 minutes
Episodes With at Least 50% Decreases in Pain
Number of episodes where the total pain score has at least a 50% reduction from baseline.
Time frame: 60 minutes
Episodes With at Least 33% Decreases in Pain
Number of episodes where the total pain score has at least a 33% reduction from baseline.
Time frame: 15 minutes
Episodes With at Least 33% Decreases in Pain
Number of episodes where the total pain score has at least a 33% reduction from baseline.
Time frame: 30 minutes
Episodes With at Least 33% Decreases in Pain
Number of episodes where the total pain score has at least a 33% reduction from baseline.
Time frame: 45 minutes
Episodes With at Least 33% Decreases in Pain
Number of episodes where the total pain score has at least a 50% reduction from baseline.
Time frame: 60 minutes
Episodes With Complete Pain Relief
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief). Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.
Time frame: 5 minutes
Episodes With Complete Pain Relief
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief).Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.
Time frame: 10 minutes
Episodes With Complete Pain Relief
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief).Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.
Time frame: 15 minutes
Episodes With Complete Pain Relief
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief). Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.
Time frame: 30 minutes
Episodes With Complete Pain Relief
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief). Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.
Time frame: 45 minutes
Episodes With Complete Pain Relief
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief). Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.
Time frame: 60 minutes
Rescue Medication Usage
Rescue medication is medication taken if adequate pain relief is not realized within 30 minutes following application of the study drug. Percentage of episodes when rescue medication was used per subject is analyzed.
Time frame: 28 Days
SPID in Neuropathic Pain Subpopulation
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome. SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest for the Neuropathic pain subpopulation for relevant time points (15, 30, 45, 60 minutes). Neuropathic pain subpopulation is a subset of ITT population who have neuropathic pain at baseline.
Time frame: 15 minutes
SPID in Neuropathic Pain Subpopulation
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome. SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest for the Neuropathic pain subpopulation for relevant time points (15, 30, 45, 60 minutes). Neuropathic pain subpopulation is a subset of ITT population who have neuropathic pain at baseline.
Time frame: 30 minutes
SPID in Neuropathic Pain Subpopulation
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome. SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest for the Neuropathic pain subpopulation for relevant time points (15, 30, 45, 60 minutes). Neuropathic pain subpopulation is a subset of ITT population who have neuropathic pain at baseline.
Time frame: 45 minutes
SPID in Neuropathic Pain Subpopulation
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome. SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest for the Neuropathic pain subpopulation for relevant time points (15, 30, 45, 60 minutes). Neuropathic pain subpopulation is a subset of ITT population who have neuropathic pain at baseline.
Time frame: 60 minutes
24FEB2006 to 14MAR2007
| Milestone | Onsolis |
|---|---|
| Started | 151 |
| Completed | 82 |
| Not completed | 69 |
| Withdrew: Adverse event | 10 |
| Withdrew: Death | 3 |
| Withdrew: Lack of efficacy | 5 |
| Withdrew: Protocol violation | 2 |
| Withdrew: Withdrawal by subject | 22 |
| Withdrew: Noncompliance and other | 27 |
| Milestone | Onsolis |
|---|---|
| Started | 82 |
| Completed | 70 |
| Not completed | 12 |
| Withdrew: Adverse event | 3 |
| Withdrew: Lack of efficacy | 1 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Noncompliance | 4 |
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome.
| Score on a scale | Onsolis | Placebo |
|---|---|---|
| Summary of Pain Intensity Differences (SPID) | 47.9 ± 3.87 | 38.1 ± 4.3 |
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome.SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest.
| Scores on a scale | Onsolis | Placebo |
|---|---|---|
| SPID | 1.8 ± 0.30 | 1.5 ± 0.36 |
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome.SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest.
| Scores on a scale | Onsolis | Placebo |
|---|---|---|
| SPID | 5.9 ± 0.80 | 4.9 ± 0.90 |
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome.SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest.
| Scores on a scale | Onsolis | Placebo |
|---|---|---|
| SPID | 12.8 ± 1.47 | 10.4 ± 1.61 |
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome.SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest.
| Scores on a scale | Onsolis | Placebo |
|---|---|---|
| SPID | 90.5 ± 6.63 | 70.8 ± 7.41 |
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome.SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest.
| Scores on a scale | Onsolis | Placebo |
|---|---|---|
| SPID | 138.0 ± 9.41 | 106.0 ± 10.58 |
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.
| Scores on a scale | Onsolis | Placebo |
|---|---|---|
| PID | 0.3 ± 0.04 | 0.3 ± 0.06 |
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.
| Scores on a scale | Onsolis | Placebo |
|---|---|---|
| PID | 0.8 ± 0.07 | 0.7 ± 0.08 |
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.
| Scores on a scale | Onsolis | Placebo |
|---|---|---|
| PID | 1.4 ± 0.09 | 1.2 ± 0.10 |
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.
| Scores on a scale | Onsolis | Placebo |
|---|---|---|
| PID | 2.5 ± 0.11 | 1.9 ± 0.14 |
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.
| Scores on a scale | Onsolis | Placebo |
|---|---|---|
| PID | 3.0 ± 0.13 | 2.3 ± 0.17 |
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.
| Scores on a scale | Onsolis | Placebo |
|---|---|---|
| PID | 3.3 ± 0.13 | 2.4 ± 0.18 |
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.
| Scores on a scale | Onsolis | Placebo |
|---|---|---|
| Pain Relief | 0.4 ± 0.04 | 0.4 ± 0.06 |
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.
| Scores on a scale | Onsolis | Placebo |
|---|---|---|
| Pain Relief | 0.8 ± 0.05 | 0.7 ± 0.06 |
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.
| Scores on a scale | Onsolis | Placebo |
|---|---|---|
| Pain Relief | 1.1 ± 0.05 | 1.0 ± 0.07 |
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.
| Scores on a scale | Onsolis | Placebo |
|---|---|---|
| Pain Relief | 1.7 ± 0.05 | 1.3 ± 0.08 |
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.
| Scores on a scale | Onsolis | Placebo |
|---|---|---|
| Pain Relief | 1.9 ± 0.06 | 1.5 ± 0.09 |
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.
| Scores on a scale | Onsolis | Placebo |
|---|---|---|
| Pain Relief | 2.1 ± 0.06 | 1.6 ± 0.09 |
Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest.Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)
| Scores on a scale | Onsolis | Placebo |
|---|---|---|
| Total Pain Relief | 2.2 ± 0.21 | 1.8 ± 0.28 |
Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest. Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)
| Scores on a scale | Onsolis | Placebo |
|---|---|---|
| Total Pain Relief | 6.1 ± 0.40 | 5.2 ± 0.54 |
Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest. Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)
| Scores on a scale | Onsolis | Placebo |
|---|---|---|
| Total Pain Relief | 11.6 ± 0.62 | 9.8 ± 0.82 |
Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest. Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)
| Scores on a scale | Onsolis | Placebo |
|---|---|---|
| Total Pain Relief | 36.1 ± 1.30 | 29.5 ± 1.79 |
Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest. Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)
| Scores on a scale | Onsolis | Placebo |
|---|---|---|
| Total Pain Relief | 64.2 ± 2.05 | 52.3 ± 2.93 |
Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest. Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)
| Scores on a scale | Onsolis | Placebo |
|---|---|---|
| Total Pain Relief | 94.8 ± 2.84 | 76.0 ± 4.16 |
Subjects evaluated their overall satisfaction with study drug at the time rescue medication was consumed or at the 60-minute time point using a 5-point categorical scale (0 = poor, 1 = fair, 2 = good, 3 = very good, and 4 = excellent).
| Scores on a scale | Onsolis | Placebo |
|---|---|---|
| Subject Overall Satisfaction With Study Drug | 2.0 ± 0.06 | 1.5 ± 0.10 |
A pain free episode is one with 0 pain intensity at the specified time point. Percentage of episodes that are pain-free per subject is analyzed.
| percentage of episodes | Onsolis | Placebo |
|---|---|---|
| Percentage of Pain Free Episodes | 1.0 ± 0.73 | 1.4 ± 1.37 |
A pain free episode is one with 0 pain intensity at the specified time point. Percentage of episodes that are pain-free per subject is analyzed.
| percentage of episodes | Onsolis | Placebo |
|---|---|---|
| Percentage of Pain Free Episodes | 1.0 ± 0.72 | 1.4 ± 1.35 |
A pain free episode is one with 0 pain intensity at the specified time point. Percentage of episodes that are pain-free per subject is analyzed.
| percentage of episodes | Onsolis | Placebo |
|---|---|---|
| Percentage of Pain Free Episodes | 2.3 ± 1.02 | 2.0 ± 1.48 |
A pain free episode is one with 0 pain intensity at the specified time point. Percentage of episodes that are pain-free per subject is analyzed.
| percentage of episodes | Onsolis | Placebo |
|---|---|---|
| Percentage of Pain Free Episodes | 5.3 ± 1.57 | 4.4 ± 1.88 |
A pain free episode is one with 0 pain intensity at the specified time point. Percentage of episodes that are pain-free per subject is analyzed.
| percentage of episodes | Onsolis | Placebo |
|---|---|---|
| Percentage of Pain Free Episodes | 10.5 ± 2.34 | 6.4 ± 2.27 |
A pain free episode is one with 0 pain intensity at the specified time point. Percentage of episodes that are pain-free per subject is analyzed.
| percentage of episodes | Onsolis | Placebo |
|---|---|---|
| Percentage of Pain Free Episodes | 14.2 ± 2.62 | 9.6 ± 2.90 |
Number of episodes where the total pain score has at least a 50% reduction from baseline.
| episodes | Onsolis | Placebo |
|---|---|---|
| Episodes With at Least 50% Decreases in Pain | 14.9 ± 2.81 | 14.7 ± 3.35 |
Number of episodes where the total pain score has at least a 50% reduction from baseline.
| episodes | Onsolis | Placebo |
|---|---|---|
| Episodes With at Least 50% Decreases in Pain | 32.8 ± 3.78 | 24.1 ± 3.87 |
Number of episodes where the total pain score has at least a 50% reduction from baseline.
| episodes | Onsolis | Placebo |
|---|---|---|
| Episodes With at Least 50% Decreases in Pain | 41.1 ± 4.11 | 30.5 ± 4.10 |
Number of episodes where the total pain score has at least a 50% reduction from baseline.
| episodes | Onsolis | Placebo |
|---|---|---|
| Episodes With at Least 50% Decreases in Pain | 46.1 ± 4.17 | 34.0 ± 4.30 |
Number of episodes where the total pain score has at least a 33% reduction from baseline.
| episodes | Onsolis | Placebo |
|---|---|---|
| Episodes With at Least 33% Decreases in Pain | 26.4 ± 3.55 | 21.3 ± 3.66 |
Number of episodes where the total pain score has at least a 33% reduction from baseline.
| episodes | Onsolis | Placebo |
|---|---|---|
| Episodes With at Least 33% Decreases in Pain | 47.3 ± 4.05 | 38.2 ± 4.45 |
Number of episodes where the total pain score has at least a 33% reduction from baseline.
| episodes | Onsolis | Placebo |
|---|---|---|
| Episodes With at Least 33% Decreases in Pain | 57.5 ± 3.93 | 46.5 ± 4.50 |
Number of episodes where the total pain score has at least a 50% reduction from baseline.
| episodes | Onsolis | Placebo |
|---|---|---|
| Episodes With at Least 33% Decreases in Pain | 64.3 ± 3.72 | 48.2 ± 4.51 |
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief). Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.
| percentage of episodes | Onsolis | Placebo |
|---|---|---|
| Episodes With Complete Pain Relief | 0.7 ± 0.66 | 0.7 ± 0.68 |
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief).Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.
| percentage of episodes | Onsolis | Placebo |
|---|---|---|
| Episodes With Complete Pain Relief | 1.0 ± 0.72 | 0.7 ± 0.68 |
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief).Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.
| percentage of episodes | Onsolis | Placebo |
|---|---|---|
| Episodes With Complete Pain Relief | 1.7 ± 0.83 | 1.3 ± 0.94 |
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief). Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.
| percentage of episodes | Onsolis | Placebo |
|---|---|---|
| Episodes With Complete Pain Relief | 5.4 ± 1.63 | 2.6 ± 1.33 |
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief). Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.
| percentage of episodes | Onsolis | Placebo |
|---|---|---|
| Episodes With Complete Pain Relief | 9.4 ± 2.18 | 6.4 ± 2.27 |
Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief). Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.
| percentage of episodes | Onsolis | Placebo |
|---|---|---|
| Episodes With Complete Pain Relief | 12.8 ± 2.49 | 7.2 ± 2.40 |
Rescue medication is medication taken if adequate pain relief is not realized within 30 minutes following application of the study drug. Percentage of episodes when rescue medication was used per subject is analyzed.
| percentage of episodes | Onsolis | Placebo |
|---|---|---|
| Rescue Medication Usage | 30.0 ± 3.53 | 44.6 ± 4.38 |
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome. SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest for the Neuropathic pain subpopulation for relevant time points (15, 30, 45, 60 minutes). Neuropathic pain subpopulation is a subset of ITT population who have neuropathic pain at baseline.
| Scores on a scale | Onsolis | Placebo |
|---|---|---|
| SPID in Neuropathic Pain Subpopulation | 13.8 ± 2.93 | 7.8 ± 3.20 |
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome. SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest for the Neuropathic pain subpopulation for relevant time points (15, 30, 45, 60 minutes). Neuropathic pain subpopulation is a subset of ITT population who have neuropathic pain at baseline.
| Scores on a scale | Onsolis | Placebo |
|---|---|---|
| SPID in Neuropathic Pain Subpopulation | 51.6 ± 8.05 | 31.8 ± 8.86 |
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome. SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest for the Neuropathic pain subpopulation for relevant time points (15, 30, 45, 60 minutes). Neuropathic pain subpopulation is a subset of ITT population who have neuropathic pain at baseline.
| Scores on a scale | Onsolis | Placebo |
|---|---|---|
| SPID in Neuropathic Pain Subpopulation | 93.0 ± 14.09 | 59.7 ± 15.63 |
Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome. SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest for the Neuropathic pain subpopulation for relevant time points (15, 30, 45, 60 minutes). Neuropathic pain subpopulation is a subset of ITT population who have neuropathic pain at baseline.
| Scores on a scale | Onsolis | Placebo |
|---|---|---|
| SPID in Neuropathic Pain Subpopulation | 137.8 ± 20.19 | 90.9 ± 22.53 |
Collected over A prior-treatment adverse event (AE) was defined as an AE that began before the first dose of the study drug. A treatment-emergent AE was defined as an AE that began on or after the initial dose of study medication up until the Follow-up Visit on Day 29.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Onsolis | — | 23/151 (15.2%) | 44/151 (29.1%) |
| Event | Onsolis |
|---|---|
| PneumoniaInfections and infestations | 6/151 |
| DehydrationMetabolism and nutrition disorders | 2/151 |
| SplenomegalyBlood and lymphatic system disorders | 1/151 |
| Gastrointestinal hemorrhageGastrointestinal disorders | 1/151 |
| HematemesisGastrointestinal disorders | 1/151 |
| Intestinal obstructionGastrointestinal disorders | 1/151 |
| Esophageal hemorrhageGastrointestinal disorders | 1/151 |
| PyrexiaGeneral disorders | 1/151 |
| Bile duct obstructionHepatobiliary disorders | 1/151 |
| Hepatic failureHepatobiliary disorders | 1/151 |
| Event | Onsolis |
|---|---|
| NauseaGastrointestinal disorders | 21/151 |
| VomitingGastrointestinal disorders | 19/151 |
| SomnolenceNervous system disorders | 10/151 |
| DehydrationMetabolism and nutrition disorders | 7/151 |
| DizzinessNervous system disorders | 7/151 |
Safety Population
| Age, Categorical(Participants) | Onsolis |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 104 |
| >=65 years | 47 |
| Age, Continuous(years) | Onsolis |
|---|---|
| Mean | 57.1 ± 12.2 |
| Sex: Female, Male(Participants) | Onsolis |
|---|---|
| Female | 85 |
| Male | 66 |
| Race (NIH/OMB)(Participants) | Onsolis |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 12 |
| White | 131 |
| More than one race | 0 |
| Unknown or Not Reported | 7 |
| Region of Enrollment(participants) | Onsolis |
|---|---|
| United States | 151 |
| Female reproductive status(Participants) | Onsolis |
|---|---|
| Post-menopausal | 43 |
| Sterile | 38 |
| Potentially able to bear children | 3 |
| Male | 67 |
| Height (inches)(Inches) | Onsolis |
|---|---|
| Mean | 66.4 ± 3.86 |
| Weight (pounds)(pounds) | Onsolis |
|---|---|
| Mean | 160.89 ± 42.011 |
The record gives a start of Feb 2006, a primary completion of Apr 2007 and a completion of Apr 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2019, 12 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
BioDelivery Sciences International